查看文章

Two comparable groups, each of which comprised 41 patients, were treated with long‐acting phenprocoumon and short‐acting acenocoumarol, respectively, for six months. When phenprocoumon was used, a significantly more stable anticoagulant effect was seen. This was reflected by a greater percentage of thrombotest values within the intended therapeutic zone ranging from 5 to 10% thrombotest activity, inclusive. Moreover, there was a difference in the facility with which patients could be kept in the therapeutic range: the number of alterations that had to be made in maintenance dose and control interval was less with phenprocoumon than with acenocoumarol.